Kalaris Therapeutics, Inc. GAAP EPS of -$0.46 beats by $0.05

Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027 Recently completed technology transfer from pilot to commercial-scale manufacturer with te

Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $

Kalaris Therapeutics (NASDAQ:KLRS) said expanded Phase 1a data for TH103 in neovascular age-related macular degeneration showed vision and retinal-anatomy improvements, with intraocular retention suggested by plasma pharmacokinetics. The company reported 41% of treatment-naive patients delaying retreatment beyond four months after one injection, and no intraocular inflammation at 2.5 mg. KLRS rose about 18% to $5.43.

Kalaris Therapeutics (NASDAQ:KLRS) shares rose about 29% after Phase 1a results for TH103 in neovascular age-related macular degeneration. The company reported vision and retinal anatomy improvements in expanded cohorts of 20 patients, with no intraocular inflammation at 2.5 mg and one transient case at 5 mg. TH103 showed lower Cmax versus leading anti-VEGF agents and longer retreatment intervals. Phase 1b/2 enrollment is ongoing, with initial data expected in H1 2027.

Kalaris Therapeutics (KLRS) reported expanded Phase 1a data for TH103 in neovascular age-related macular degeneration. The study included 17 treatment-naive and 3 treatment-experienced patients with 6-month follow-up. Plasma Cmax was 27 to 53 times lower than leading anti-VEGF agents, with 29% needing no anti-VEGF during follow-up. Safety showed no IOI at 2.5 mg and one transient IOI at 5 mg.

ON Holding AG (ONON) reported Q3 2026 earnings with EPS of $0.54 (beating estimates by 42.11%) and revenue of $931.40M (in line with expectations). Despite the earnings beat, shares fell 8.07% intraday. The company has shown sequential revenue growth and consistent EPS beats, but revenue estimates have slightly declined. Next catalysts include Q4 earnings, product launches, and wholesale trends.